Abstract 5315: Anti-tumor activity of KRASG12C inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agentsHusain Yar Khan, Asfar S. Azmi, Ramzi M. Mohammad et al.|Cancer Research|2022Cited by 0